527 Neoadjuvant multimodal treatment approach for stage III non-small cell lung cancer (NSCLC): Results of a prospective phase II trial

Lung Cancer ◽

10.1016/s0169-5002(97)89907-2 ◽

1997 ◽

Vol 18 ◽

pp. 135

Author(s):

M. Thomas ◽

C. Rübe ◽

M. Semik ◽

F. Klinke ◽

M. von Eiff ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Multimodal Treatment ◽

Phase Ii Trial ◽

Treatment Approach ◽

Small Cell Lung ◽

Multimodal Treatment Approach ◽

Prospective Phase

Download Full-text

401P A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)

Annals of Oncology ◽

10.1016/j.annonc.2020.10.395 ◽

2020 ◽

Vol 31 ◽

pp. S1399-S1400

Author(s):

S. Igawa ◽

R. Noro ◽

K. Kubota ◽

K. Naoki ◽

A. Bessho ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Low Dose ◽

Egfr Mutation ◽

Phase Ii Trial ◽

Small Cell Lung ◽

Prospective Phase

Download Full-text

Prospective phase II trial of pre-resection thoracoscopic (VATS) restaging following neoadjuvant therapy for IIIA(N2) non-small cell lung cancer (NSCLC): Results of CALGB 39803

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.7065 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 7065-7065 ◽

Author(s):

M. T. Jaklitsch ◽

L. Gu ◽

D. H. Harpole ◽

T. A. D’Amico ◽

R. J. McKenna ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Neoadjuvant Therapy ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell Lung ◽

Prospective Phase

Download Full-text

Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1093/annonc/mdy424.067 ◽

2018 ◽

Vol 29 ◽

pp. viii744 ◽

Author(s):

E.S. Kim ◽

V. Velcheti ◽

T. Mekhail ◽

T.A. Leal ◽

J.E. Dowell ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Predictive Biomarker ◽

Primary Efficacy ◽

Small Cell Lung ◽

Mutational Burden ◽

Prospective Phase

Download Full-text

Vimentin (EMT Marker Protein) Score Predicts Resistance to Erlotinib and Radiation Therapy for Patients With Stage III Non-small Cell Lung Cancer on a Prospective Phase II Trial

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2012.07.069 ◽

2012 ◽

Vol 84 (3) ◽

pp. S24-S25

Author(s):

R.U. Komaki ◽

Y.B. Kim ◽

I.I. Wistuba ◽

X. Tang ◽

R. Meyn ◽

...

Keyword(s):

Lung Cancer ◽

Radiation Therapy ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Marker Protein ◽

Small Cell Lung ◽

Prospective Phase

Download Full-text

Pemetrexed monotherapy in patients with advanced non-small cell lung cancer who have had prior chemotherapy: A prospective phase II trial

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.19137 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 19137-19137

Author(s):

H. Lee ◽

M. Ahn ◽

J. Ahn ◽

J. Kwon ◽

S. Lee ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell Lung ◽

Prior Chemotherapy ◽

Prospective Phase

Download Full-text

A prospective phase II trial of carboplatin (CBDCA) and nab-paclitaxel (nabPTX) for advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD)

Annals of Oncology ◽

10.1093/annonc/mdz260.094 ◽

2019 ◽

Vol 30 ◽

pp. v647

Author(s):

T. Harada ◽

H. Asahina ◽

S. Oizumi ◽

K. Takamura ◽

M. Harada ◽

...

Keyword(s):

Lung Cancer ◽

Interstitial Lung Disease ◽

Small Cell Lung Cancer ◽

Lung Disease ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell Lung ◽

Prospective Phase

Download Full-text

Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy

Yearbook of Pulmonary Disease ◽

10.1016/s8756-3452(09)79376-4 ◽

2010 ◽

Vol 2010 ◽

pp. 152-153

Author(s):

L.T. Tanoue

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Stereotactic Body Radiotherapy ◽

Phase Ii Trial ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

Prospective Phase

Download Full-text

Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non–small cell lung cancer: Results of CALGB Protocol 39803

Journal of Thoracic and Cardiovascular Surgery ◽

10.1016/j.jtcvs.2012.12.069 ◽

2013 ◽

Vol 146 (1) ◽

pp. 9-16 ◽

Author(s):

Michael T. Jaklitsch ◽

Lin Gu ◽

Todd Demmy ◽

David H. Harpole ◽

Thomas A. D'Amico ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Neoadjuvant Therapy ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell Lung ◽

Prospective Phase

Download Full-text

Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1093/annonc/mdz394.081 ◽

2019 ◽

Vol 30 ◽

pp. v919-v920 ◽

Author(s):

M. Socinski ◽

V. Velcheti ◽

T. Mekhail ◽

Y.K. Chae ◽

T.A. Leal ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Predictive Biomarker ◽

Small Cell Lung ◽

Mutational Burden ◽

Prospective Phase

Download Full-text

1365P A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.1679 ◽

2020 ◽

Vol 31 ◽

pp. S872-S873

Author(s):

R. Noro ◽

S. Igawa ◽

A. Bessho ◽

T. Hirose ◽

S. Tsuneo ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Low Dose ◽

Egfr Mutation ◽

Phase Ii Trial ◽

Small Cell Lung ◽

Prospective Phase

Download Full-text